ArticleSovremennye tekhnologii v meditsine2026
Immunohistochemical Detection of Microglia Using Iba-1 as a Marker in Health and Disease.
Article in Sovremennye tekhnologii v meditsine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapeutic Antitoxoplasmosis Potential ofJournal of tropical medicine · 2026Article
- Treadmill training induces sex-dependent changes in hippocampal epigenetic patterns and plaque-associated microglial morphology in aged TgF344 rats.Frontiers in neuroscience · 2026Article
- Opposite regulatory effects ofFrontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Materials and Methods: In the study we used brain samples from Wistar rats at different ages: 7 days of postnatal development (n=18), 14 days of postnatal development (n=18), 4-6 months (n=22); the brain samples from 3-6-month-old SHR (spontaneously hypertensive rats) male rats (n=4); human cerebral cortex samples (n=10). Rabbit polyclonal antibodies against calcium-binding protein Iba-1 (Biocare Medical, USA) were used to detect microglia immunohistochemically followed by light and confocal laser microscopy. A previously developed original technique was applied to simultaneously detect microglial cells and amyloid plaques. Results: Iba-1 protein in microglial cells was shown to be present in grey and white matter in all cerebral regions under study. Microglial cells in different regions were noted to be characterized by pronounced structural and functional features when stained for Iba-1. In addition to microglial cells, in the rat brain there were found other Iba-1-immunopositive macrophages, which were tissue cerebral macrophages differing from microgliocytes by specific morphology and localization. Iba-1 protein was demonstrated to be present in microglial cells in all investigated stages of postnatal development that makes Iba-1 an appropriate marker for comparative ontogenetical studies of microglial cells. The localization of Iba-1 in the bodies and processes of microgliocytes enables to more clearly identify the complex ramified cell morphology and make three-dimensional reconstructions. In the brain of spontaneously hypertensive rats (SHR line rats) the Iba-1-immunopositive microglia were shown to have a number of structural and functional features indicating the moderate activation of microglia. 48 h after ischemic injury, an anomalously great number of large Iba-1-immunopositive cells with amoeboid morphology were detected in the gray matter of the striatum in an ipsilateral hemisphere near the injured area in the rat brain. Microglial cells in human cerebral cortex were noted to be localized in the majority of the detected amyloid plaques and characterized by amoeboid morphology indicating their severe activation. Conclusion: The presented findings suggest Iba-1 protein to be a reliable and universal microglial marker. The immunohistochemical detection of the protein enables to identify and analyze qualitatively and quantitatively microglial cells in different brain regions in human and laboratory animals under normal and pathological conditions. The limitations of using Iba-1 as a marker of microglia include the inability to determine the microglial activation vector and the difficulty in distinguishing between microglia and infiltrating macrophages of the brain in pathology. In such cases, it is necessary to improve the technology for detecting microglia that can be based on using a multi-marker analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.